

INTERIM FORMULARY UPDATE

The following recommendations, made at the April 17, 2015 meeting of the Executive Formulary Committee, are approved:

Product(s) **approved to be added** to the DADS/DSHS Drug Formulary based on New Drug Applications:
The Committee did not receive any new drug applications.

Product(s) **deleted** from the DADS/DSHS Drug Formulary based on **Drug Formulary Sectional Review-Psychotropic Agents**

- **Delete the following from the Formulary due to lack of purchases for the past year:**

Generic Name	Brand Name	Dosage forms to be deleted	Dosage forms still available
Amoxapine	Asendin®	Tablet: 25 mg, 50 mg, 100 mg, 150 mg	None
Maprotiline	Ludiomil®	Tablet: 25 mg, 50 mg, 75 mg	None
Trimipramine	Surmontil®	Capsule 25 mg, 50 mg, 100 mg	None

- **Delete the following discontinued items:**

Generic Name	Brand Name	Dosage forms to be deleted	Dosage forms still available
Clorazepate	Tranxene®	Tablet, sustained release: 11.25 mg, 22.5 mg	Tablet: 3.75 mg, 7.5 mg, 15 mg
Diazepam	Valium®	Gel, rectal: 5 mg, 15 mg	Gel, rectal: 2.5 mg, 10 mg, 20 mg Injection: 5 mg/ml Solution, oral: 1 mg/ml, 5 mg/ml Tablet: 2 mg, 5 mg, 10 mg
Paroxetine	Paxil®	Tablet, controlled release: 50 mg	Suspension: 10 mg/5 ml Tablet: 10 mg, 20 mg, 30 mg, 40 mg Tablet, controlled release: 12.5 mg, 25 mg, 37.5 mg
Thioridazine	Mellaril®	Tablet: 15 mg, 150 mg, 200 mg	Tablet: 10 mg, 25 mg, 50 mg, 100 mg
Thiothixene	Navane®	Capsule: 20 mg	Capsule: 1 mg, 2 mg, 5 mg, 10 mg
Hydroxyzine	Atarax®, Vistaril®	Tablet: 100 mg	Capsule: 25 mg, 50 mg, 100 mg Injection: 25 mg/ml, 50 mg/ml Suspension: 25 mg/5 ml Syrup: 10 mg/5 ml Tablet: 10 mg, 25 mg, 50 mg

Other **Recommendation(s)/addition(s)/revisions(s)** to the drug listings in the DADS/DSHS Drug Formulary

- Change the name of the “Miscellaneous Agents” under the Antidepressant section to “Miscellaneous Antidepressant Agents”
- Add oxcarbazepine (Trileptal®), topiramate (Topamax®) to the Mood Stabilizer section
- Change valproate to valproic acid in the mood stabilizers section
- Merge the “Anxiolytics and Hypnotics” section with the “Benzodiazepines” subsection under “Psychotropic Agents.”
 - Change the name of this section to “Benzodiazepine anxiolytics and hypnotics”
 - Add midazolam (Versed®) to this section
- Delete the “Miscellaneous Psychotropic Agents” subsection. As a result of this deletion:
 - Add a new subsection “Miscellaneous Anxiolytics and Hypnotics.” Add the following to this subsection:
 - Diphenhydramine (Benadryl®)
 - Trazodone (Desyrel®)

- Zaleplon (Sonata®)
- Zolpidem (Ambien®)
- Buspirone (BuSpar®)
- Hydroxyzine (Atarax®, Vistaril®)
- Prazosin (Minipress®)
- Add a new subsection “Other ADHD Agents” under the “Stimulants” section. Add the following to this subsection
 - Guanfacine (Tenex®)
 - Clonidine (Catapres®)
- Delete naloxone (Narcan®) as it is in the “Antidotes/Deterrents/Poison Control Agents”
- Delete naltrexone (ReVia®) as it is in the “Chemical Dependency Adjuncts”

Approved



Ann Richards, Pharm., D., BCPP
Pharmacy Services Director
San Antonio State Hospital